For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...
Zacks.com on MSN12h
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded UseUltragenyx Pharmaceutical RARE announced that the European Commission (EC) has expanded the eligible patient population for ...
GlobalData on MSN15h
FDA accepts Sentynl’s Menkes disease therapy NDA for priority reviewSentynl took over the therapy’s development and commercialisation from Fortress Biotech's subsidiary Cyprium Therapeutics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback